The “China Precision Medical Plan” has developed rapidly since its implementation in 2016. According to relevant statistics, at present, the global precision medicine market has exceeded 60 billion US dollars, of which accurate diagnosis is about 10 billion US dollars, precision treatment is about 50 billion US dollars, and the global precision medicine industry will maintain about 15% growth rate in the next 3-5 years.

Despite the huge market potential in the field of precision medicine , returning to the industry, the technology-oriented precision medical enterprises and artificial intelligence medical enterprises are generally not strong in commercialization. In addition, they are subject to market access policies and clinical research. Under the influence of other factors, the degree of commercialization of foreign advanced scientific research results in China is not enough.

At present, a number of enterprises have started to accumulate in the CSO (contract sales organization) model, such as: Yiteng Pharmaceutical, China Pioneer Pharmaceutical, and Kangzhe Pharmaceutical. These companies introduce innovative patented drugs from preclinical research or clinical trials to the Chinese market through cooperation with multinational pharmaceutical companies and overseas professional pharmaceutical companies.

In this model, although it can help innovate technology or commercialize projects, companies cannot have the core rights of products. In this regard, Mei Yao Bio founder Zhu Yuyan believes that this is the core difference between Mei Ao Bio and CSO-based enterprises. At the same time, it is also the key to the closure of the commercialization of the Chinese market by Mei Ao Bio-assisted innovation projects.

Since its inception, Zhu Yuyan has positioned Meiao Bio as a world-class precision medical innovation platform, and has helped the world to have independent intellectual property rights and clinically proven precision medical technology and products, from project introduction, results transformation to marketing. The entire business closed loop. Less than two years after its establishment, it has entered into strategic cooperation with Oxford Cancer Biomarker Company (OCB) and US 20/20 GeneSystems.

As a bridge connecting innovative medical technology, products and doctors, patients, Mei Ao Bio plans to expand into more scenarios after completing the entire product line in the field of tumor diagnosis and treatment. At this stage, Mei Ao Bio has obtained three technical licenses from OCB, ColoTox (Centre, fluorouracil drug toxicity prediction), ColoProg (Chang Lefu, colorectal cancer patients with recurrence risk prediction), ColoPredict (Chang Lepu, Prediction of hereditary risk of colorectal cancer).

Among them, ColoProg has completed technology transfer and overseas clinical research, and is the first to be listed in China. It is the first objective and quantitative stratification assessment tool for colorectal cancer recurrence risk in China, and it is also the first completion of Piaomei Bio. A successful case of commercial closed loop.

Zhu Yiyan told Lieyun that Meiao Bio has a layout on both the B and C sides. At the B end, Mei Ao Bio will complete the technology transfer or redevelopment, clinical research, guide, and report on the project through agency authorization. Work on certificates, fees, clinical promotion, etc., accelerate the listing and promotion of products, and serve doctors and terminal patients.

Among them, in the screening method of the project, Mei Ao Bio will choose to cooperate with innovative projects that meet clinical and patient needs, have independent patents and are in clinical stage. On the C-end patient side, Mei Ao Bio will develop a diagnostic product for the Chinese population through cooperation with the Oxford Cancer Biomarker Company in the UK, which is expected to be launched next year.

In order to step up the transformation and landing of the project, Mei Ao Bio has set up the Meiao Medical Testing Center in Meishan, Ningbo. It has been approved by the Ningbo Health and Medical Organization's medical and health institutions in October 2017, and plans to get the EU and CAP/CLIA for 2 years. Certification.

It is reported that the medical inspection laboratory established by OCB at the Magdalen Center in Oxford will be mainly responsible for basic research, and the Meiao Medical Testing Center will be responsible for the transformation of results, and the two will cooperate to create overseas markets.

In addition to precision medicine, artificial intelligence is also a key business area of ​​Mei Ao Bio. As a “Tencent Eco-Partner”, Mei Ao Bio mainly plays a role in helping technology and clinical connectivity, that is, connecting technology providers such as Tencent and hospital demanders for joint project development and marketing.

At present, Mei Ao Bio has entered into a strategic cooperation with Tencent's team at Huashan Hospital to carry out project cooperation including AI product development in brain surgery. Mei Ao Bio will participate in the whole process as a member of the project team.

Referring to the core value of Mei Ao's biology, Zhu Yiyan believes that there are two points: the ability to connect and integrate resources. Through one year of accumulation, there are projects to find out every two weeks, ensuring that Mayo Bio can continue to reach excellent projects; resource integration capabilities are mainly reflected in the closed loop of commercialization, in addition to cooperation with some CRO companies. Mei Ao Bio has also accumulated a wealth of legal teams, organizational association resources, and expert resources.

On the team side, Mei Yao Bio CEO Zhu Yiyan served as General Manager of Catalent Greater China, former Boehringer Ingelheim China VP; core members mainly from the medical, market, BD of Bayer, Merck, GlaxoSmithKline, Novartis, Squibb and other companies , Admission Department and Haigui Research Doctor.

In May of this year, Meiao Bio has obtained tens of millions of rounds of financing from Puhua Capital, and there is no financing plan at present.

Green Acrylic Tape

Green Acrylic Tape,Strong Acrylic Tape,Acrylic Mounting Tape,Vhb Acrylic Foam Tape

Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.jerrytapes.com